Banner - Infusion Center Locator
Infusion Center Locator Disclaimer
Daiichi Sankyo, Inc. is providing this service to help patients find an infusion center in their area that has experience with Injectafer® (ferric carboxymaltose injection). Daiichi Sankyo, Inc. does not receive payment for this service and does not endorse, recommend, have jurisdiction over, and is not responsible for the actions of any healthcare professional. You are ultimately responsible for the selection of a doctor and it is an important decision that you should consider carefully. This locator tool is just one source of information available to you.
This locator website (Site) may provide links or references to other Web sites not affiliated with Daiichi Sankyo, or its parents, subsidiaries, affiliates, licensees, sponsors, agents, partners, successors, and assigns (“DSI"). DSI is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from users' access to such sites. Links to other sites are provided only as a convenience to users of our site. However, DSI has used reasonable efforts to verify that the URLs referring to external Web sites are correct, point the visitor to relevant organizations, and were active at the last revision of the DSI site.
By using this Site, you agree that:
- DSI makes no express or implied warranties about the accuracy or completeness of information contained in this Site’s listings;
- DSI shall not, under any circumstance, be liable to you or any other person for any decision or action taken by you or any person arising from or related to information contained in the Site;
- DSI does not make any endorsement of, or recommendations or referrals to any particular location as a result of the location being listed on the Site;
- DSI is not responsible for verifying the accuracy of any skills, education, experience, or ability to practice of any location listed on this Site and you have the sole responsibility to verify that a particular location has the appropriate qualifications and skills to treat you; and
- You are solely responsible for the content of any and all communications or other interactions with any location listed on the Site.
Important Safety Information
Injectafer® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease.
IMPORTANT SAFETY INFORMATION
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition. In most cases, hypophosphatemia resolved within three months.
Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).
The following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: cardiac disorders: tachycardia; general disorders and administration site conditions: chest discomfort, chills, pyrexia; metabolism and nutrition disorders: hypophosphatemia; musculoskeletal and connective tissue disorders: arthralgia, back pain, hypophosphatemic osteomalacia (rarely reported event); nervous system disorders: syncope; respiratory, thoracic and mediastinal disorders: dyspnea; skin and subcutaneous tissue disorders: angioedema, erythema, pruritus, urticaria.
You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.